 | • レポートコード：MRC2-11QY12815 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は潰瘍性大腸炎免疫薬 のグローバル市場について調査・分析したレポートです。種類別（アダリムマブ、セルトリズマブペゴル、トファシチニブ、エタネルセプト、ゴリムマブ、アバタセプト、インフリキシマブ、その他）市場規模、用途別（関節リウマチ、クローン病（CD）、強直性脊椎炎（AS）、乾癬（Ps）、潰瘍性大腸炎（UC））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別潰瘍性大腸炎免疫薬 の競争状況、市場シェア ・世界の潰瘍性大腸炎免疫薬 市場：種類別市場規模 2015年-2020年（アダリムマブ、セルトリズマブペゴル、トファシチニブ、エタネルセプト、ゴリムマブ、アバタセプト、インフリキシマブ、その他） ・世界の潰瘍性大腸炎免疫薬 市場：種類別市場規模予測 2021年-2026年（アダリムマブ、セルトリズマブペゴル、トファシチニブ、エタネルセプト、ゴリムマブ、アバタセプト、インフリキシマブ、その他） ・世界の潰瘍性大腸炎免疫薬 市場：用途別市場規模 2015年-2020年（関節リウマチ、クローン病（CD）、強直性脊椎炎（AS）、乾癬（Ps）、潰瘍性大腸炎（UC）） ・世界の潰瘍性大腸炎免疫薬 市場：用途別市場規模予測 2021年-2026年（関節リウマチ、クローン病（CD）、強直性脊椎炎（AS）、乾癬（Ps）、潰瘍性大腸炎（UC）） ・北米の潰瘍性大腸炎免疫薬 市場分析：米国、カナダ ・ヨーロッパの潰瘍性大腸炎免疫薬 市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの潰瘍性大腸炎免疫薬 市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の潰瘍性大腸炎免疫薬 市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの潰瘍性大腸炎免疫薬 市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Janssen Biotech, Inc.、Bristol-Myers Squibb Company、AbbVie Inc.、UCBCares、AMGEN、Celltrion Healthcare、Biogen、Genentech USA, Inc.、ROCHE、Pfizer Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Ulcerative Colitis Immunology Drugs Market
The global Ulcerative Colitis Immunology Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Ulcerative Colitis Immunology Drugs Scope and Market Size
Ulcerative Colitis Immunology Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ulcerative Colitis Immunology Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Ulcerative Colitis Immunology Drugs market is segmented into
Adalimumab
Certolizumab Pegol
Tofacitinib
Etanercept
Golimumab
Abatacept
Infliximab
Others
Segment by Application, the Ulcerative Colitis Immunology Drugs market is segmented into
Rheumatoid Arthritis
Crohn’s Disease(CD)
Ankylosing Spondylitis(AS)
Psoriasis(Ps)
Ulcerative Colitis(UC)
Regional and Country-level Analysis
The Ulcerative Colitis Immunology Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Ulcerative Colitis Immunology Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Ulcerative Colitis Immunology Drugs Market Share Analysis
Ulcerative Colitis Immunology Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Ulcerative Colitis Immunology Drugs business, the date to enter into the Ulcerative Colitis Immunology Drugs market, Ulcerative Colitis Immunology Drugs product introduction, recent developments, etc.
The major vendors covered:
Janssen Biotech, Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
UCBCares
AMGEN
Celltrion Healthcare
Biogen
Genentech USA, Inc.
ROCHE
Pfizer Inc.
1 Study Coverage
1.1 Ulcerative Colitis Immunology Drugs Product Introduction
1.2 Market Segments
1.3 Key Ulcerative Colitis Immunology Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by Type
1.4.2 Adalimumab
1.4.3 Certolizumab Pegol
1.4.4 Tofacitinib
1.4.5 Etanercept
1.4.6 Golimumab
1.4.7 Abatacept
1.4.8 Infliximab
1.4.9 Others
1.5 Market by Application
1.5.1 Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by Application
1.5.2 Rheumatoid Arthritis
1.5.3 Crohn’s Disease(CD)
1.5.4 Ankylosing Spondylitis(AS)
1.5.5 Psoriasis(Ps)
1.5.6 Ulcerative Colitis(UC)
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Ulcerative Colitis Immunology Drugs Market Size, Estimates and Forecasts
2.1.1 Global Ulcerative Colitis Immunology Drugs Revenue 2015-2026
2.1.2 Global Ulcerative Colitis Immunology Drugs Sales 2015-2026
2.2 Global Ulcerative Colitis Immunology Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Ulcerative Colitis Immunology Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Ulcerative Colitis Immunology Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Ulcerative Colitis Immunology Drugs Competitor Landscape by Players
3.1 Ulcerative Colitis Immunology Drugs Sales by Manufacturers
3.1.1 Ulcerative Colitis Immunology Drugs Sales by Manufacturers (2015-2020)
3.1.2 Ulcerative Colitis Immunology Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Ulcerative Colitis Immunology Drugs Revenue by Manufacturers
3.2.1 Ulcerative Colitis Immunology Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Ulcerative Colitis Immunology Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Ulcerative Colitis Immunology Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Ulcerative Colitis Immunology Drugs Revenue in 2019
3.2.5 Global Ulcerative Colitis Immunology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Ulcerative Colitis Immunology Drugs Price by Manufacturers
3.4 Ulcerative Colitis Immunology Drugs Manufacturing Base Distribution, Product Types
3.4.1 Ulcerative Colitis Immunology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Ulcerative Colitis Immunology Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Ulcerative Colitis Immunology Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Ulcerative Colitis Immunology Drugs Market Size by Type (2015-2020)
4.1.1 Global Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020)
4.1.2 Global Ulcerative Colitis Immunology Drugs Revenue by Type (2015-2020)
4.1.3 Ulcerative Colitis Immunology Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Ulcerative Colitis Immunology Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Ulcerative Colitis Immunology Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Ulcerative Colitis Immunology Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Ulcerative Colitis Immunology Drugs Market Size by Application (2015-2020)
5.1.1 Global Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020)
5.1.2 Global Ulcerative Colitis Immunology Drugs Revenue by Application (2015-2020)
5.1.3 Ulcerative Colitis Immunology Drugs Price by Application (2015-2020)
5.2 Ulcerative Colitis Immunology Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Ulcerative Colitis Immunology Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Ulcerative Colitis Immunology Drugs by Country
6.1.1 North America Ulcerative Colitis Immunology Drugs Sales by Country
6.1.2 North America Ulcerative Colitis Immunology Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Type
6.3 North America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Ulcerative Colitis Immunology Drugs by Country
7.1.1 Europe Ulcerative Colitis Immunology Drugs Sales by Country
7.1.2 Europe Ulcerative Colitis Immunology Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Ulcerative Colitis Immunology Drugs Market Facts & Figures by Type
7.3 Europe Ulcerative Colitis Immunology Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Ulcerative Colitis Immunology Drugs by Region
8.1.1 Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Region
8.1.2 Asia Pacific Ulcerative Colitis Immunology Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Ulcerative Colitis Immunology Drugs Market Facts & Figures by Type
8.3 Asia Pacific Ulcerative Colitis Immunology Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Ulcerative Colitis Immunology Drugs by Country
9.1.1 Latin America Ulcerative Colitis Immunology Drugs Sales by Country
9.1.2 Latin America Ulcerative Colitis Immunology Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Type
9.3 Central & South America Ulcerative Colitis Immunology Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Ulcerative Colitis Immunology Drugs by Country
10.1.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country
10.1.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Corporation Information
11.1.2 Janssen Biotech, Inc. Description and Business Overview
11.1.3 Janssen Biotech, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Products Offered
11.1.5 Janssen Biotech, Inc. Related Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Description and Business Overview
11.2.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Products Offered
11.2.5 Bristol-Myers Squibb Company Related Developments
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Corporation Information
11.3.2 AbbVie Inc. Description and Business Overview
11.3.3 AbbVie Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Products Offered
11.3.5 AbbVie Inc. Related Developments
11.4 UCBCares
11.4.1 UCBCares Corporation Information
11.4.2 UCBCares Description and Business Overview
11.4.3 UCBCares Sales, Revenue and Gross Margin (2015-2020)
11.4.4 UCBCares Ulcerative Colitis Immunology Drugs Products Offered
11.4.5 UCBCares Related Developments
11.5 AMGEN
11.5.1 AMGEN Corporation Information
11.5.2 AMGEN Description and Business Overview
11.5.3 AMGEN Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AMGEN Ulcerative Colitis Immunology Drugs Products Offered
11.5.5 AMGEN Related Developments
11.6 Celltrion Healthcare
11.6.1 Celltrion Healthcare Corporation Information
11.6.2 Celltrion Healthcare Description and Business Overview
11.6.3 Celltrion Healthcare Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Products Offered
11.6.5 Celltrion Healthcare Related Developments
11.7 Biogen
11.7.1 Biogen Corporation Information
11.7.2 Biogen Description and Business Overview
11.7.3 Biogen Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Biogen Ulcerative Colitis Immunology Drugs Products Offered
11.7.5 Biogen Related Developments
11.8 Genentech USA, Inc.
11.8.1 Genentech USA, Inc. Corporation Information
11.8.2 Genentech USA, Inc. Description and Business Overview
11.8.3 Genentech USA, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Products Offered
11.8.5 Genentech USA, Inc. Related Developments
11.9 ROCHE
11.9.1 ROCHE Corporation Information
11.9.2 ROCHE Description and Business Overview
11.9.3 ROCHE Sales, Revenue and Gross Margin (2015-2020)
11.9.4 ROCHE Ulcerative Colitis Immunology Drugs Products Offered
11.9.5 ROCHE Related Developments
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Corporation Information
11.10.2 Pfizer Inc. Description and Business Overview
11.10.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Products Offered
11.10.5 Pfizer Inc. Related Developments
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Corporation Information
11.1.2 Janssen Biotech, Inc. Description and Business Overview
11.1.3 Janssen Biotech, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Products Offered
11.1.5 Janssen Biotech, Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Ulcerative Colitis Immunology Drugs Market Estimates and Projections by Region
12.1.1 Global Ulcerative Colitis Immunology Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Ulcerative Colitis Immunology Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Ulcerative Colitis Immunology Drugs Sales Forecast (2021-2026)
12.2.2 North America: Ulcerative Colitis Immunology Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Ulcerative Colitis Immunology Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Ulcerative Colitis Immunology Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Ulcerative Colitis Immunology Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Ulcerative Colitis Immunology Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Ulcerative Colitis Immunology Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Ulcerative Colitis Immunology Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Ulcerative Colitis Immunology Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Ulcerative Colitis Immunology Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Ulcerative Colitis Immunology Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Ulcerative Colitis Immunology Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Ulcerative Colitis Immunology Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Ulcerative Colitis Immunology Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Ulcerative Colitis Immunology Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Ulcerative Colitis Immunology Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Ulcerative Colitis Immunology Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Ulcerative Colitis Immunology Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Ulcerative Colitis Immunology Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Ulcerative Colitis Immunology Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Ulcerative Colitis Immunology Drugs Market Segments
Table 2. Ranking of Global Top Ulcerative Colitis Immunology Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Adalimumab
Table 5. Major Manufacturers of Certolizumab Pegol
Table 6. Major Manufacturers of Tofacitinib
Table 7. Major Manufacturers of Etanercept
Table 8. Major Manufacturers of Golimumab
Table 9. Major Manufacturers of Abatacept
Table 10. Major Manufacturers of Infliximab
Table 11. Major Manufacturers of Others
Table 12. Global Ulcerative Colitis Immunology Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 13. Global Ulcerative Colitis Immunology Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 14. Global Ulcerative Colitis Immunology Drugs Sales by Regions 2015-2020 (K Pcs)
Table 15. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Regions (2015-2020)
Table 16. Global Ulcerative Colitis Immunology Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Ulcerative Colitis Immunology Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Ulcerative Colitis Immunology Drugs Sales Share by Manufacturers (2015-2020)
Table 19. Global Ulcerative Colitis Immunology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Ulcerative Colitis Immunology Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ulcerative Colitis Immunology Drugs as of 2019)
Table 21. Ulcerative Colitis Immunology Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Ulcerative Colitis Immunology Drugs Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Ulcerative Colitis Immunology Drugs Price (2015-2020) (USD/Pcs)
Table 24. Ulcerative Colitis Immunology Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Ulcerative Colitis Immunology Drugs Product Type
Table 26. Date of International Manufacturers Enter into Ulcerative Colitis Immunology Drugs Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 29. Global Ulcerative Colitis Immunology Drugs Sales Share by Type (2015-2020)
Table 30. Global Ulcerative Colitis Immunology Drugs Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Ulcerative Colitis Immunology Drugs Revenue Share by Type (2015-2020)
Table 32. Ulcerative Colitis Immunology Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 34. Global Ulcerative Colitis Immunology Drugs Sales Share by Application (2015-2020)
Table 35. North America Ulcerative Colitis Immunology Drugs Sales by Country (2015-2020) (K Pcs)
Table 36. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2015-2020)
Table 37. North America Ulcerative Colitis Immunology Drugs Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Ulcerative Colitis Immunology Drugs Revenue Market Share by Country (2015-2020)
Table 39. North America Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 40. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Table 41. North America Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 42. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Table 43. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2015-2020) (K Pcs)
Table 44. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2015-2020)
Table 45. Europe Ulcerative Colitis Immunology Drugs Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Country (2015-2020)
Table 47. Europe Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 48. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 50. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Region (2015-2020) (K Pcs)
Table 52. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Ulcerative Colitis Immunology Drugs Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Ulcerative Colitis Immunology Drugs Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 56. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 58. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Table 59. Latin America Ulcerative Colitis Immunology Drugs Sales by Country (2015-2020) (K Pcs)
Table 60. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Ulcerative Colitis Immunology Drugs Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Ulcerative Colitis Immunology Drugs Revenue Market Share by Country (2015-2020)
Table 63. Latin America Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 64. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Table 65. Latin America Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 66. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2015-2020) (K Pcs)
Table 68. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Type (2015-2020) (K Pcs)
Table 72. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Application (2015-2020) (K Pcs)
Table 74. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Table 75. Janssen Biotech, Inc. Corporation Information
Table 76. Janssen Biotech, Inc. Description and Major Businesses
Table 77. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Janssen Biotech, Inc. Product
Table 79. Janssen Biotech, Inc. Recent Development
Table 80. Bristol-Myers Squibb Company Corporation Information
Table 81. Bristol-Myers Squibb Company Description and Major Businesses
Table 82. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Bristol-Myers Squibb Company Product
Table 84. Bristol-Myers Squibb Company Recent Development
Table 85. AbbVie Inc. Corporation Information
Table 86. AbbVie Inc. Description and Major Businesses
Table 87. AbbVie Inc. Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. AbbVie Inc. Product
Table 89. AbbVie Inc. Recent Development
Table 90. UCBCares Corporation Information
Table 91. UCBCares Description and Major Businesses
Table 92. UCBCares Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. UCBCares Product
Table 94. UCBCares Recent Development
Table 95. AMGEN Corporation Information
Table 96. AMGEN Description and Major Businesses
Table 97. AMGEN Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. AMGEN Product
Table 99. AMGEN Recent Development
Table 100. Celltrion Healthcare Corporation Information
Table 101. Celltrion Healthcare Description and Major Businesses
Table 102. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Celltrion Healthcare Product
Table 104. Celltrion Healthcare Recent Development
Table 105. Biogen Corporation Information
Table 106. Biogen Description and Major Businesses
Table 107. Biogen Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Biogen Product
Table 109. Biogen Recent Development
Table 110. Genentech USA, Inc. Corporation Information
Table 111. Genentech USA, Inc. Description and Major Businesses
Table 112. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Genentech USA, Inc. Product
Table 114. Genentech USA, Inc. Recent Development
Table 115. ROCHE Corporation Information
Table 116. ROCHE Description and Major Businesses
Table 117. ROCHE Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. ROCHE Product
Table 119. ROCHE Recent Development
Table 120. Pfizer Inc. Corporation Information
Table 121. Pfizer Inc. Description and Major Businesses
Table 122. Pfizer Inc. Ulcerative Colitis Immunology Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Pfizer Inc. Product
Table 124. Pfizer Inc. Recent Development
Table 125. Global Ulcerative Colitis Immunology Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 126. Global Ulcerative Colitis Immunology Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 127. Global Ulcerative Colitis Immunology Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 128. Global Ulcerative Colitis Immunology Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 129. North America: Ulcerative Colitis Immunology Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 130. North America: Ulcerative Colitis Immunology Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Europe: Ulcerative Colitis Immunology Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 132. Europe: Ulcerative Colitis Immunology Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Asia Pacific: Ulcerative Colitis Immunology Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 134. Asia Pacific: Ulcerative Colitis Immunology Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 135. Latin America: Ulcerative Colitis Immunology Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 136. Latin America: Ulcerative Colitis Immunology Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Middle East and Africa: Ulcerative Colitis Immunology Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 138. Middle East and Africa: Ulcerative Colitis Immunology Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 140. Key Challenges
Table 141. Market Risks
Table 142. Main Points Interviewed from Key Ulcerative Colitis Immunology Drugs Players
Table 143. Ulcerative Colitis Immunology Drugs Customers List
Table 144. Ulcerative Colitis Immunology Drugs Distributors List
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Ulcerative Colitis Immunology Drugs Product Picture
Figure 2. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Adalimumab Product Picture
Figure 4. Certolizumab Pegol Product Picture
Figure 5. Tofacitinib Product Picture
Figure 6. Etanercept Product Picture
Figure 7. Golimumab Product Picture
Figure 8. Abatacept Product Picture
Figure 9. Infliximab Product Picture
Figure 10. Others Product Picture
Figure 11. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2020 & 2026
Figure 12. Rheumatoid Arthritis
Figure 13. Crohn's Disease(CD)
Figure 14. Ankylosing Spondylitis(AS)
Figure 15. Psoriasis(Ps)
Figure 16. Ulcerative Colitis(UC)
Figure 17. Ulcerative Colitis Immunology Drugs Report Years Considered
Figure 18. Global Ulcerative Colitis Immunology Drugs Market Size 2015-2026 (US$ Million)
Figure 19. Global Ulcerative Colitis Immunology Drugs Sales 2015-2026 (K Pcs)
Figure 20. Global Ulcerative Colitis Immunology Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 21. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region (2015-2020)
Figure 22. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region in 2019
Figure 23. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region (2015-2020)
Figure 24. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Region in 2019
Figure 25. Global Ulcerative Colitis Immunology Drugs Sales Share by Manufacturer in 2019
Figure 26. The Top 10 and 5 Players Market Share by Ulcerative Colitis Immunology Drugs Revenue in 2019
Figure 27. Ulcerative Colitis Immunology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type (2015-2020)
Figure 29. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type in 2019
Figure 30. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type (2015-2020)
Figure 31. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Type in 2019
Figure 32. Global Ulcerative Colitis Immunology Drugs Market Share by Price Range (2015-2020)
Figure 33. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application (2015-2020)
Figure 34. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2019
Figure 35. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application (2015-2020)
Figure 36. Global Ulcerative Colitis Immunology Drugs Revenue Market Share by Application in 2019
Figure 37. North America Ulcerative Colitis Immunology Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 38. North America Ulcerative Colitis Immunology Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 39. North America Ulcerative Colitis Immunology Drugs Sales Market Share by Country in 2019
Figure 40. North America Ulcerative Colitis Immunology Drugs Revenue Market Share by Country in 2019
Figure 41. U.S. Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 42. U.S. Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Canada Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 44. Canada Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. North America Ulcerative Colitis Immunology Drugs Market Share by Type in 2019
Figure 46. North America Ulcerative Colitis Immunology Drugs Market Share by Application in 2019
Figure 47. Europe Ulcerative Colitis Immunology Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 48. Europe Ulcerative Colitis Immunology Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 49. Europe Ulcerative Colitis Immunology Drugs Sales Market Share by Country in 2019
Figure 50. Europe Ulcerative Colitis Immunology Drugs Revenue Market Share by Country in 2019
Figure 51. Germany Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Germany Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. France Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. France Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. U.K. Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. U.K. Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Italy Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 58. Italy Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Russia Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 60. Russia Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Europe Ulcerative Colitis Immunology Drugs Market Share by Type in 2019
Figure 62. Europe Ulcerative Colitis Immunology Drugs Market Share by Application in 2019
Figure 63. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 64. Asia Pacific Ulcerative Colitis Immunology Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 65. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Market Share by Region in 2019
Figure 66. Asia Pacific Ulcerative Colitis Immunology Drugs Revenue Market Share by Region in 2019
Figure 67. China Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. China Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Japan Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Japan Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. South Korea Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. South Korea Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. India Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. India Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Australia Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Australia Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Taiwan Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Taiwan Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Indonesia Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Indonesia Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Thailand Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Thailand Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Malaysia Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Malaysia Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Philippines Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 86. Philippines Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Vietnam Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 88. Vietnam Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Asia Pacific Ulcerative Colitis Immunology Drugs Market Share by Type in 2019
Figure 90. Asia Pacific Ulcerative Colitis Immunology Drugs Market Share by Application in 2019
Figure 91. Latin America Ulcerative Colitis Immunology Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 92. Latin America Ulcerative Colitis Immunology Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 93. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share by Country in 2019
Figure 94. Latin America Ulcerative Colitis Immunology Drugs Revenue Market Share by Country in 2019
Figure 95. Mexico Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Mexico Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Brazil Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 98. Brazil Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Argentina Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 100. Argentina Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Latin America Ulcerative Colitis Immunology Drugs Market Share by Type in 2019
Figure 102. Latin America Ulcerative Colitis Immunology Drugs Market Share by Application in 2019
Figure 103. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 104. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 105. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share by Country in 2019
Figure 106. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Market Share by Country in 2019
Figure 107. Turkey Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. Turkey Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 110. Saudi Arabia Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. U.A.E Ulcerative Colitis Immunology Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 112. U.A.E Ulcerative Colitis Immunology Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. Middle East and Africa Ulcerative Colitis Immunology Drugs Market Share by Type in 2019
Figure 114. Middle East and Africa Ulcerative Colitis Immunology Drugs Market Share by Application in 2019
Figure 115. North America Ulcerative Colitis Immunology Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. North America Ulcerative Colitis Immunology Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Europe Ulcerative Colitis Immunology Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Europe Ulcerative Colitis Immunology Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Asia Pacific Ulcerative Colitis Immunology Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Asia Pacific Ulcerative Colitis Immunology Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Latin America Ulcerative Colitis Immunology Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 122. Latin America Ulcerative Colitis Immunology Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 124. Middle East and Africa Ulcerative Colitis Immunology Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Porter's Five Forces Analysis
Figure 126. Channels of Distribution
Figure 127. Distributors Profiles
Figure 128. Bottom-up and Top-down Approaches for This Report
Figure 129. Data Triangulation
Figure 130. Key Executives Interviewed
免疫学の世界市場（～2026年） The immune system protects the body from harmful things such as a virus, germs, and diseases like cancer. It is a network of cells, molecules: and organs present throughout the body. The immune system attacks the foreign substance that is found in the body. The body identifies and destroys the abnor…- 免疫学治療薬の世界市場（～2026年） The immune system is an assembly of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies various threats like bacteria, viruses, and parasites and distinguishes them from body's healthy tissues. When the immune system weakness and l…
- 体軸性脊椎関節炎薬の世界市場（～2026年） Market Analysis and Insights: Global Axial Spondyloarthritis Drugs Market The global Axial Spondyloarthritis Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Axial Spondyloarthritis Drugs Scope and Market Size Axi…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- 黄斑変性症（AMD）の世界市場（～2026年） Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. The North American region is the most lucrative market, ow…